Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.
From Tatva Chintan Pharma Chem Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters.
- Agro Products: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027.
- Electrolyte Salts: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispatches.
- Pharma and Agro Intermediates: Four agro and four pharma molecules expected to reach full potential in 2-3 years, collectively addressing a revenue potential of INR300-350 crore.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
- This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates.
- Additional capex rounds may be considered for scaling up certain agro products as demand grows.
- Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization.
- Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback.
- Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline.
- New large-scale agro intermediate commercialization has commenced, with production activities progressing as planned.
- Validation batches for new pharma and agro intermediates are underway, with commercialization expected from December 2025 to the second half of 2026.
- The semiconductor product pipeline includes products in piloting, with expected revenues ranging INR50-100 crores.
2 more points management made on order book & pipeline
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Bodal Chemicals Ltd (Q2 FY26)
Q2 FY26 consolidated revenue from operations: Rs 4,804.5 mn, up 11.2% YoY from Rs 4,321.2 mn (Page 10). Key concall takeaways from Bodal Chemicals Ltd's Q2…
- Chemcon Speciality Chemicals Ltd (Q2 FY26)
Q2 FY26 revenue from operations: ₹53.7 crore, up 2% YoY (vs ₹52.6 crore in Q2 FY25) [Page 9, 6] . Key concall takeaways from Chemcon Speciality Chemicals Ltd's…
- Valiant Organics Ltd (Q2 FY26)
Q2-FY26 consolidated revenue from operations: INR 1,573 million, down 1.8% year-on-year (Page 12). Key concall takeaways from Valiant Organics Ltd's Q2 FY26…
- Indian Phosphate Ltd (Q2 FY26)
H1 FY 25-26 revenue increased by ~15% to ₹451 crores versus ₹385 crores in H1 FY 24-25. Key concall takeaways from Indian Phosphate's Q2 FY26 earnings call…
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q2 FY26 results?
SDA Segment: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.